Show simple item record

 
dc.contributorIDIAP Jordi Gol
dc.contributor.authorGiner-Soriano, Maria
dc.contributor.authorGomez-Lumbreras, Ainhoa
dc.contributor.authorVedia, Cristina
dc.contributor.authorOuchi, Dan
dc.contributor.authorMorros, Rosa
dc.date.accessioned2022-06-10T08:50:08Z
dc.date.available2022-06-10T08:50:08Z
dc.date.issued2022-06-08
dc.identifier.citationGiner‑Soriano M, Gomez‑Lumbreras A, Vedia C, Ouchi D, Morros R. Risk of thrombotic events and other complications in anticoagulant users infected with SARS-CoV-2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain). BMC Prim Care. 2022 Jun 8;23(1):147.
dc.identifier.issn2731-4553
dc.identifier.urihttp://hdl.handle.net/11351/7659
dc.descriptionCOVID-19; Oral anticoagulants; Thrombotic events; Primary health care
dc.description.abstractBackground: The risk of thromboembolic events and COVID-19 complications in anticoagulated patients once hos‑ pitalized has been widely analyzed. We aim to assess these outcomes in primary health care (PHC) patients chronically treated with oral anticoagulants (OAC) in comparison with non-treated. Methods: Cohort study including adults with COVID-19 diagnosis in the PHC records in Catalonia, Spain; from March to June 2020. Patients were matched between exposed and non-exposed to OAC based on age and gender in a 1:2 design. Data source is the Information System for Research in Primary Care (SIDIAP). Results: We included 311,542 individuals with COVID-19. After propensity score matching, we obtained a cohort of 20,360 people, 10,180 exposed and 10,180 non-exposed to OAC. Their mean age was 79.9 and 52.1% were women. Patients exposed to OAC had a higher frequency of comorbidities than non-exposed. Anticoagulated patients had a higher risk of hospital admission (IRR 1.16, 95% CI 1.03–1.29), and of stroke and pulmonary embolism than nonanticoagulated (IRR 1,80, 95% CI 1.06–3.06). The risk of pneumonia was not diferent between groups (IRR 1.04, 95% CI 0.84–1.30). We found a lower risk of death in patients exposed to OAC (IRR 0.60, 95% CI 0.55–0.65). Conclusions: OAC users in our study had more comorbidities and were older than non-users, well known risks for hospitalization being confrmed with our results. We also found in our study that OAC exposure was not associated to an increased risk in the mortality rate, and it was associated with higher risks of hospital admission and thrombo‑ embolic events, although we cannot assess the efect of the interventions applied during hospital admission on the outcomes studied, as our database is a PHC database.
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofseriesBMC Primary Care;23(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectFarmacoepidemiologia
dc.subjectAnticoagulants (Medicina) - Efectes secundaris
dc.subjectCOVID-19 (Malaltia)
dc.subject.meshPharmacoepidemiology
dc.subject.meshAnticoagulants
dc.subject.meshCoronavirus Infections
dc.titleRisk of thrombotic events and other complications in anticoagulant users infected with SARS‑CoV‑2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12875-022-01752-5
dc.subject.decsfarmacoepidemiología
dc.subject.decsanticoagulantes
dc.subject.decsinfecciones por Coronavirus
dc.relation.publishversionhttps://doi.org/10.1186/s12875-022-01752-5
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Giner Soriano M, Gomez Lumbreras A, Ouchi D] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Vedia C] Unitat de Farmàcia, Servei d’Atenció Primària Barcelonès Nord i Maresme, Institut Català de la Salut (ICS), Badalona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Morros R] Fundació Institut Universitari per a la Recerca a L’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. Institut Català de la Salut (ICS), Barcelona, Spain. Plataforma SCReN, UICEC IDIAP Jordi Gol, Barcelona, Spain
dc.identifier.pmid35676639
dc.relation.projectidEUPAS Register: EUPAS37205
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record